Crispr Infuses First Human in Landmark Gene-Editing Study
- Drugmaker treats first patient in beta thalassemia trial
- Milestone follows clinical hold, ethical uproar on rogue study
Source: Getty Images
This article is for subscribers only.
Crispr Therapeutics AG shares surged after the company said it has treated the first human with the same genetic technology that shares its name in an early-stage study.
Crispr Therapeutics and partner Vertex Pharmaceuticals Inc. said on Monday morning that the first patient in a trial using CTX001, a therapy created using Crispr technology, as a treatment for the rare blood disease, beta thalassemia, received the one-time medicine. The pair also announced the enrollment of the first patient has started in a parallel study for the medicine in sickle-cell disease with the first dosing on track for mid-year.